{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:58:53Z","timestamp":1787014733420,"version":"build-2736575974"},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T00:00:00Z","timestamp":1302825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background\u2002<\/jats:bold>\n                    Cutaneous leishmaniasis is an infectious re\u2010emerging disease that has increased in incidence worldwide. Antimony, a highly toxic drug, remains the first choice therapy to treat it. Liposomal amphotericin B is active against Leishmania and is less toxic than antimony.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective\u2002<\/jats:bold>\n                    To compare low\u2010dose liposomal amphotericin B with\n                    <jats:italic>N<\/jats:italic>\n                    \u2010methyl glucamine for the treatment of American cutaneous leishmaniasis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients\/Methods\u2002<\/jats:bold>\n                    In a controlled open\u2010label trial 35 patients with a localized form of American cutaneous leishmaniasis were included. They were allocated to a first group treated with 1.5\u2003mg\/kg\/day of liposomal amphotericin B for 5\u2003days, or to a second one treated with 20\u2003mgSbV\/kg\/day of\n                    <jats:italic>N<\/jats:italic>\n                    \u2010methyl glucamine for 20\u2003days.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2002<\/jats:bold>\n                    In the first group, 50% and 81% of patients experienced a clinical cure and clinical improvement respectively. There was a 100% clinical cure in the second group.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion\u2002<\/jats:bold>\n                    Liposomal amphotericin B seems to be promising and safe for the treatment of American cutaneous leishmaniasis.\n                  <\/jats:p>","DOI":"10.1111\/j.1468-3083.2011.04070.x","type":"journal-article","created":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T04:04:05Z","timestamp":1302840245000},"page":"331-335","source":"Crossref","is-referenced-by-count":27,"title":["A pilot study comparing low\u2010dose liposomal amphotericin B with\n                    <i>N<\/i>\n                    \u2010methyl glucamine for the treatment of American cutaneous leishmaniasis"],"prefix":"10.1111","volume":"26","author":[{"given":"J.O.C.","family":"Motta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.N.R.","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,4,15]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2010.03851.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70209-8"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/tropej\/fmp073"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1708-8305.2008.00286.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.06.088"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.46841-0"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2006.02.022"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/01.idc.0000155842.95374.b7","article-title":"Treatment of relapsed cutaneous Leishmania (Viannia) braziliensis infection with liposomal amphotericin B","volume":"13","author":"Devlin RK","year":"2005","journal-title":"Infect Dis Clin Pract"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.2174\/092986707780362862"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1516-93322006000200003"},{"key":"e_1_2_6_12_2","first-page":"75","article-title":"Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi\u2010centre trial","volume":"87","author":"Davidson RN","year":"1994","journal-title":"Q J Med"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.6.938"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(96)90270-9"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(96)90271-0"},{"key":"e_1_2_6_16_2","first-page":"230","article-title":"Efficacy and tolerability of liposomal amphotericin B (AmBisome) in the treatment of visceral leishmaniasis in Brazil","volume":"1","author":"Freire M","year":"1997","journal-title":"Braz J Infect Dis"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(97)70165-3"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7310.419"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06670.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/18.6.1024"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(97)90404-1"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.4.752"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.2.341"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.06.044"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(91)90029-X"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.4103\/0974-777X.62886"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0037-86822006000200001"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0037-86822000000600004"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2011.04070.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2011.04070.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T07:36:16Z","timestamp":1697355376000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2011.04070.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,15]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1111\/j.1468-3083.2011.04070.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04070.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,15]]}}}